(RTTNews) - Japanese healthcare firm Daiichi Sankyo Co., Ltd (DSKYF.PK) announced Friday the appointment of Hiroyuki Okuzawa as Chief Executive Officer, succeeding Sunao Manabe, with effect from ...

In December, Astra and Daiichi withdrew an application in the EU for the drug to treat a type of lung cancer after feedback from regulatory advisers. Mixed results from a late-stage trial showed ...

Malaysia's IHH Healthcare said on Thursday its unit is seeking compensation of up to 109.3 billion rupees ($1.25 billion) from Japan's Daiichi Sankyo for its stake buy in India's Fortis Healthcare.

PETALING JAYA: IHH Healthcare Bhd says its unit is seeking compensation of up to 109.3 billion rupees (RM5.46bil) from Japan’s Daiichi Sankyo for its stake buy in India’s Fortis Healthcare.

Malaysia's IHH Healthcare may be entitled to damages of up to $1.25 billion from Japan's Daiichi Sankyo for blocking its bid for control of Indian hospital operator Fortis , according to a report ...

Disclaimer: This article has been developed and funded by Daiichi Sankyo. Daiichi Sankyo has more than 120 years of experience and scientific expertise. In 2019, they entered the oncology market ...

Several medicines are poised to reach new heights after winning key endorsements from European drug regulators. The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP ...

To recap, NTK in October 2023 filed a lawsuit in the Tokyo District Court alleging that Daiichi Sankyo caused losses by preventing NTK from proceeding with open offers to buy a stake in Indian ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Daiichi Sankyo is turning to the German city of Heidelberg for help developing antibodies. The Japanese pharma giant is teaming up with independent research institute BioMed X to form a new ...

Jefferies analyst Stephen Barker maintained a Buy rating on Daiichi Sankyo Company (DSKYF – Research Report) on January 19 and set a price target of Yen7,600.00. Stephen Barker has given his Buy ...

A next-generation form of chemotherapy from AstraZeneca and Daiichi Sankyo has won Food and Drug Administration authorization for a form of breast cancer, the first U.S. approval for a drug for ...